---
title: "阿斯利康的高血压药物获得美国批准"
type: "News"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/286724028.md"
description: "阿斯利康已获得美国对其高血压药物 Baxfendy（前称 baxdrostat）的批准，该药物通过靶向醛固酮来降低血压。公司预计年峰值销售额将超过 50 亿美元。此项批准增强了阿斯利康在心血管和肾脏治疗领域的产品组合，此前其糖尿病药物 Farxiga 的专利已到期。FDA 的决定基于成功的晚期试验，显示该药物在无法控制的高血压患者中有效。阿斯利康计划到 2030 年推出 20 种新药，目标是实现 800 亿美元的收入"
datetime: "2026-05-18T06:30:31.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286724028.md)
  - [en](https://longbridge.com/en/news/286724028.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286724028.md)
---

# 阿斯利康的高血压药物获得美国批准

By Adria Calatayud

AstraZeneca said it received U.S. approval for a new hypertension treatment, getting the green light to launch a drug the U.K. pharmaceutical company expects to generate multibillion-dollar annual sales at its peak.

The drug, known until now as baxdrostat, will be marketed under the brand name Baxfendy, the company said Monday. The approval expands AstraZeneca's cardiovascular, renal and metabolism portfolio shortly after diabetes drug Farxiga--its biggest product in that therapeutic area and the bestselling medicine in the company's history--went off patent in the U.S.

AstraZeneca said that Baxfendy treats hypertension in a new way by targeting aldosterone, a hormone that raises blood pressure.

Ruud Dobber, executive vice president of AstraZeneca's biopharmaceuticals business, said the approval brings a new treatment to a disease that has had little therapeutic progress for the past two decades.

The U.S. Food and Drug Administration approved the drug as a treatment of hypertension in adults in combination with other medications, the company said. The decision was based on results of a late-stage clinical trial that showed the drug reduced blood pressure in patients with uncontrolled hypertension who were on two or more medications, it added.

Executives at AstraZeneca previously said revenue from the product could top $5 billion at its peak. The drug is one of the 20 new medicines the company aims to launch by the end of the decade, as part of its goal to achieve revenue of $80 billion by 2030.

AstraZeneca, which gained control of Baxfendy through its acquisition of CinCor Pharma in 2023, is looking to expand its portfolio in cardiovascular, renal and metabolism diseases with new products such as its experimental drug, elecoglipron, for weight loss.

Write to Adria Calatayud at adria.calatayud@wsj.com

(END) Dow Jones Newswires

May 18, 2026 02:20 ET (06:20 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

### 相关股票

- [AZN.US](https://longbridge.com/zh-CN/quote/AZN.US.md)
- [AZN.UK](https://longbridge.com/zh-CN/quote/AZN.UK.md)
- [CINC.US](https://longbridge.com/zh-CN/quote/CINC.US.md)

## 相关资讯与研究

- [阿斯利康高血压药物获美国批准](https://longbridge.com/zh-CN/news/286741013.md)
- [574 亿大药，迎来首仿](https://longbridge.com/zh-CN/news/285477451.md)
- [强生重症肌无力治疗新药获国家药监局批准上市](https://longbridge.com/zh-CN/news/287196062.md)
- [默沙东 ADC 药物达 III 期主要终点](https://longbridge.com/zh-CN/news/286929703.md)
- [ADC 没有冬天，但一半的人已经穿上棉袄](https://longbridge.com/zh-CN/news/287153509.md)